Literature DB >> 24652019

Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients.

Alexandra Sima1, Romulus Timar, Adrian Vlad, Bogdan Timar, Mihaela Rosu, Isabel Dan, Roxana Sirli, Alina Popescu, Ioan Sporea.   

Abstract

OBJECTIVE: Nonalcoholic fatty liver disease represents an excessive fat accumulation in the liver of patients with no other liver disease and no history of alcohol abuse. It is associated with insulin resistance, being more prevalent in obesity and type 2 diabetes. Our aim was to assess the prevalence of fatty liver and nonalcoholic steatohepatitis in patients with type 2 diabetes and to evaluate the influence of obesity on its prevalence.
METHODS: We included 348 type 2 diabetes patients (age: 18-65 years), without a history of liver disease or alcohol abuse. We assessed demographical data, medical history, physical examination, blood tests, and abdominal ultrasonography.
RESULTS: The prevalence of liver steatosis in our group was 87.1 %, with no significant differences between men and women. Patients with steatosis had higher abdominal circumference, body mass index (BMI; p = 0.001), and serum triglyceride (p < 0.0001), HbA1c (p < 0.001), and alaninaminotranspherase levels (ALT, p = 0.001). The value of BMI, abdominal circumference, and serum triglyceride levels independently influenced the prevalence of liver steatosis; the influence of HbA1c level was not significant. In 23.9 % of the patients with steatosis, we found elevated liver enzymes.
CONCLUSION: We observed an elevated prevalence of nonalcoholic fatty liver disease (87.1 %) in type 2 diabetic patients. The factors influencing this prevalence are BMI, abdominal circumference,and serum triglyceride levels.

Entities:  

Mesh:

Year:  2014        PMID: 24652019     DOI: 10.1007/s00508-014-0530-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  20 in total

1.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

Review 2.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.

Authors:  Brad Q Starley; Christopher J Calcagno; Stephen A Harrison
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

Review 3.  [Steatosis and steatohepatitis in diabetic patient].

Authors:  P Hůlek; I Dresslerová
Journal:  Vnitr Lek       Date:  2011-04

Review 4.  Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.

Authors:  Briohny W Smith; Leon A Adams
Journal:  Nat Rev Endocrinol       Date:  2011-05-10       Impact factor: 43.330

5.  Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.

Authors:  Janus P Ong; Hazem Elariny; Rochelle Collantes; Abraham Younoszai; Vikas Chandhoke; H David Reines; Zachary Goodman; Zobair M Younossi
Journal:  Obes Surg       Date:  2005-03       Impact factor: 4.129

6.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Authors:  Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison
Journal:  Gastroenterology       Date:  2010-09-19       Impact factor: 22.682

7.  Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases.

Authors:  U L Mathiesen; L E Franzén; H Aselius; M Resjö; L Jacobsson; U Foberg; A Frydén; G Bodemar
Journal:  Dig Liver Dis       Date:  2002-07       Impact factor: 4.088

Review 8.  Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.

Authors:  Iliana Doycheva; Niraj Patel; Michael Peterson; Rohit Loomba
Journal:  J Diabetes Complications       Date:  2013-01-09       Impact factor: 2.852

9.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Authors:  M Prashanth; H K Ganesh; M V Vima; M John; T Bandgar; Shashank R Joshi; S R Shah; P M Rathi; A S Joshi; Hemangini Thakkar; P S Menon; N S Shah
Journal:  J Assoc Physicians India       Date:  2009-03

10.  Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data.

Authors:  A N Mavrogiannaki; I N Migdalis
Journal:  Int J Endocrinol       Date:  2013-04-03       Impact factor: 3.257

View more
  4 in total

1.  Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: A population-based cross-sectional study.

Authors:  Ueamporn Summart; Bandit Thinkhamrop; Nittaya Chamadol; Narong Khuntikeo; Metha Songthamwat; Christina Sunyoung Kim
Journal:  F1000Res       Date:  2017-09-04

2.  A Non-Invasive Prediction Model for Non-Alcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Based on the Population of Northern Urumqi, China.

Authors:  Mingyue Xue; Xiaoping Yang; Yuan Zou; Tao Liu; Yinxia Su; Cheng Li; Hua Yao; Shuxia Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-02-02       Impact factor: 3.168

3.  Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients.

Authors:  Oana Irina Gavril; Lidia Iuliana Arhire; Radu Sebastian Gavril; Madalina Ioana Zota; Andreea Gherasim; Otilia Nita; Andrei Drugescu; Andrei Catalin Oprescu; Irina Mihaela Esanu; Florin Mitu; Mariana Graur; Laura Mihalache
Journal:  Medicina (Kaunas)       Date:  2021-11-15       Impact factor: 2.430

4.  Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease.

Authors:  Stefan Traussnigg; Emina Halilbasic; Harald Hofer; Petra Munda; Tatjana Stojakovic; Günter Fauler; Karl Kashofer; Martin Krssak; Michael Wolzt; Michael Trauner
Journal:  Wien Klin Wochenschr       Date:  2020-09-15       Impact factor: 1.704

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.